Shattuck Labs, Inc.

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for inflammatory, immune-mediated, and oncological diseases. Its lead candidate, SL-325, is a death receptor 3 (DR3) blocking monoclonal antibody currently in Phase I clinical trials for conditions involving tumor necrosis factor-like ligand 1A (TL1A). The company also has SL-425, a half-life extended version of SL-325, undergoing IND-enabling chronic good laboratory practices toxicity studies. Additionally, Shattuck Labs is developing preclinical DR3-based bispecific antibodies for inflammatory bowel disease and other immune-mediated indications, as well as an oncology program called TRIM7.

Shattuck Labs, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol STTK. The company's stock is traded in United States Dollars (USD), reflecting its primary listing in the U.S. capital markets.

Shattuck Labs operates within the Healthcare sector, specifically in the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on researching and developing novel antibody-based treatments for inflammatory, immune-mediated, and oncological diseases, which is typical for firms in this industry.

Shattuck Labs is headquartered in Austin, Texas, United States. The company primarily serves the U.S. market, as indicated by its country and region designations. Its clinical trials and preclinical programs are conducted in the United States, targeting diseases prevalent in this region.